Year All2026202520242023 Aileron Therapeutics Announces Rebranding to Rein Therapeutics January 10, 2025 Read more Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights November 14, 2024 Read more Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) November 13, 2024 Read more Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma October 31, 2024 Read more Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis October 12, 2024 Read more Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) September 23, 2024 Read more Aileron Therapeutics to Present at the 8th Annual IPF Summit August 19, 2024 Read more Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights August 14, 2024 Read more Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference July 30, 2024 Read more Aileron Therapeutics to be Included in the Russell Microcap® Index July 1, 2024 Read more
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights November 14, 2024 Read more
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) November 13, 2024 Read more
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma October 31, 2024 Read more
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis October 12, 2024 Read more
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) September 23, 2024 Read more
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights August 14, 2024 Read more
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference July 30, 2024 Read more
